Literature DB >> 21467017

Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites.

Jennifer M Nelson1, Patricia M Griffin, Timothy F Jones, Kirk E Smith, Elaine Scallan.   

Abstract

Antimicrobial and antimotility agents are not recommended for the treatment of Shiga toxin-producing Escherichia coli O157 infection. In our study, many persons with Shiga toxin-producing E. coli O157 infection took antimicrobial (62%) and antimotility agents (32%); 43 (29%) of 146 reported commencing antimicrobial treatment after laboratory confirmation. Efforts are needed to promote practice guidelines.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21467017     DOI： 10.1093/cid/cir087

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  11 in total

1.  An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. coli O157:H7 in an animal model of diarrheal disease.

Authors:  Jennifer M Ritchie; Jennifer L Greenwich; Brigid M Davis; Roderick T Bronson; Dana Gebhart; Steven R Williams; David Martin; Dean Scholl; Matthew K Waldor
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

2.  Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.

Authors:  Craig S Wong; Jody C Mooney; John R Brandt; Amy O Staples; Srdjan Jelacic; Daniel R Boster; Sandra L Watkins; Phillip I Tarr
Journal:  Clin Infect Dis       Date:  2012-03-19       Impact factor: 9.079

3.  Antibiotic Susceptibility Profiles and Frequency of Resistance Genes in Clinical Shiga Toxin-Producing Escherichia coli Isolates from Michigan over a 14-Year Period.

Authors:  Sanjana Mukherjee; Heather M Blankenship; Jose A Rodrigues; Rebekah E Mosci; James T Rudrik; Shannon D Manning
Journal:  Antimicrob Agents Chemother       Date:  2021-08-23       Impact factor: 5.191

4.  Phenethyl isothiocyanate inhibits shiga toxin production in enterohemorrhagic Escherichia coli by stringent response induction.

Authors:  Dariusz Nowicki; Monika Maciąg-Dorszyńska; Wioletta Kobiela; Anna Herman-Antosiewicz; Alicja Węgrzyn; Agnieszka Szalewska-Pałasz; Grzegorz Węgrzyn
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

Review 5.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

Review 6.  A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults.

Authors:  Wolfgang Fischbach; Viola Andresen; Marion Eberlin; Tobias Mueck; Peter Layer
Journal:  Front Med (Lausanne)       Date:  2016-10-14

Review 7.  Acute gastroenteritis.

Authors:  Nancy S Graves
Journal:  Prim Care       Date:  2013-07-19       Impact factor: 2.907

Review 8.  Management of hemolytic-uremic syndrome in children.

Authors:  Silviu Grisaru
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-06-12

Review 9.  Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials.

Authors:  Marion Eberlin; Min Chen; Tobias Mueck; Jan Däbritz
Journal:  BMC Pediatr       Date:  2018-04-03       Impact factor: 2.125

10.  Enterohemorrhagic E. coli (EHEC)-Secreted Serine Protease EspP Stimulates Electrogenic Ion Transport in Human Colonoid Monolayers.

Authors:  C Ming Tse; Julie G In; Jianyi Yin; Mark Donowitz; Michele Doucet; Jennifer Foulke-Abel; Fernando Ruiz-Perez; James P Nataro; Nicholas C Zachos; James B Kaper; Olga Kovbasnjuk
Journal:  Toxins (Basel)       Date:  2018-09-01       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.